Fairmount Funds Management LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 4:31 pm Sale | 2026-03-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 1,855,644 3.100% | -1,855,800 (-50.00%) | Filing |
| 2025-08-14 4:03 pm Purchase | 2025-06-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,711,444 6.300% | 508,646 (+15.88%) | Filing |
| 2025-02-14 3:45 pm Unchanged | 2024-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,202,798 6.600% | 0 (Unchanged) | Filing |
| 2024-11-14 4:15 pm Purchase | 2024-09-30 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 3,202,798 6.800% | 1,071,429 (+50.27%) | Filing |
| 2024-02-14 3:45 pm Purchase | 2023-12-31 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 2,131,369 5.200% | 6,744 (+0.32%) | Filing |
| 2023-04-27 10:00 am Purchase | 2023-04-18 | 13G | ENLIVEN THERAPEUTICS INC ELVN | Fairmount Funds Management LLC | 2,124,625 5.170% | 2,124,625 (New Position) | Filing |